EGFR and non-small cell lung carcinoma: The acquired EGFR C797S mutation mediates resistance to third-generation EGFR inhibitors in ∼40% of osimertinib-treated NSCLC patients.93 Both cis and trans mutations of C797S and T790M were observed in resistant cases.